

3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H) Metal (II) complexes of -thione (HAMMOT) Synthesis and research on antibiotics

P.Navitha, P.Sujatha, Sk. Shakira

^{1,2,3}Assistant Professor, Department of H & S, Brilliant Institute of Engineering and Technology, Hyderabad, India

Abstract

The newly discovered clubbed compound 3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H) With the use of the Mannich condensation process, -thione (HAMMOT) was created (4-methoxyphenyl) Formaldehyde, 1,3,4-oxadiazole-2(3H)-thione, and hydrochloride of 5-amino-8-hydroxyquinoline. Later, utilising transition metal (II) salts, several transition metal (II) complexes of new ligands (HAMMOT) were created. Spectroscopic methods and elemental analysis were used to examine the novel clubbed molecule (HAMMOT) and its metal (II) complexes. Also, the agar cup plate technique was used to test the in vitro antibacterial properties of all the freshly synthesized compounds. Modest to excellent antibacterial and antifungal activity was exhibited by a novel clubbed molecule and its metal (II) complexes.

Keywords: 1,3,4-oxadiazole-2(3H)-thione, 5-amino-8-hydroxyquinoline, Mannich condensation, transition metal (II) complexes, spectral studies, antimicrobial activity

Introduction

Due to the global expansion of diseases that are drug-resistant, novel antimicrobial medicines are always in demand¹. Bacterial multidrug resistance (MDR) poses a severe hazard to human health². Hence, it is necessary to produce antibacterial compounds with novel structural features and wide antimicrobial efficacy against diseases with resistance. Combined compounds with various pharmacophores may have beneficial biological activities³.

Due to their many pharmacological and biological properties, nitrogen heterocycles are significant in medicinal chemistry. 8-hydroxyquinoline derivatives (8HQs) play an important role in medicinal chemistry due to their wide range of biological features, including their effectiveness against amoebas, malaria, allergies, cancer, leishmaniasis, and fungi. 4-12. Several 8HQ derivatives have been shown to exhibit powerful antineurodegenerative effects, including 5-chloro-7-iodo-8-hydroxyquinoline (CQ), 5-((4-(prop-2-ynyl)piperazin-1-yl)methyl)quinolin-8-ol, 5-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol, and 5-((4-(2-hydroxyethyl) effects¹³. As a Cu chelator, CQ exerts selective antiangiogenesis activity¹⁴ toward breast cancer¹⁵, prostate cancer¹⁶ leukemia, and myeloma¹⁷ with less effect on normal cells. Antimicrobial properties like antibacterial¹⁸⁻²⁰, antimalarial²¹⁻²³, antiviral²⁴, antitubercular²⁵, and antidental plaque activities²⁶⁻²⁷ of 8HQ and its derivatives have also been reported. 8HQ has been found to be non-carcinogenic and is employed for in vitro assays as well as genetic toxicity²⁸. 8-Hydroxyquinoline, at concentrations of 10-50 µg/mL, rapidly and selectively inhibits RNA synthesis in fission yeast. Protein synthesis, cell growth and uridine uptake are not immediately affected. The mechanism of inhibition appears to be by chelation of divalent cations required for RNA synthesis. The effects of 8-hydroxyquinoline are remarkably similar to those of the antibiotic lomofungin²⁹. Iron bound to the lipophilic chelator (8HQ), results in substantial DNA-strand breakage of cultured human lung cells³⁰. The Fe-8HQ complex acts as a cytostatic drug³¹. Due to high lipophilicity, 8HQ can penetrate bacterial cell membrane and arrive at metal-binding site of bacterial enzymes. The metal-8HQ complex dissociates into a 1:1 ratio of 8HQ-metal charged complex and 8HQ free ligand³². The charged 8HQ metal complex can bind and block the

metal-binding sites on bacterial enzymes that offer the antimicrobial activity³³. In addition, the dissociated free ligand of 8HQ possesses high chelating ability that could bind metallic prosthetic groups of microbial enzymes thereby leading to the inhibition of enzymatic activity³². 8HQ-uracil metal complexes exhibited growth inhibition against many strains of Gram-positive and Gram-negative bacteria including resistant pathogens, such as *S. aureus*, *Enterococcus faecalis*, and *Candida albicans*³⁴. Among the groups of tested metal-binding compounds, 8HQ exhibited high antiviral activity with approximately 50-fold higher activity³⁵.

Like 8HQ, Oxadiazole core also is a fertile source of bioactivity in the field of medicinal chemistry owing to wide-ranging pharmacological and biological activities. A large number of oxadiazole compounds have shown a wide range of antimicrobial activity 1,3,4-oxadiazoles have shown therapeutic values like antimicrobial anticancer⁴⁸, anti-inflammatory⁴⁹, anticonvulsant⁵⁰, CNS Stimulant⁵¹, antihypertensive⁵², hypnotic and sedative activities⁵³. Quinoline-oxadiazole hybrid derivatives have shown potent antibacterial as well as antifungal activities⁵⁴.

Hence, it was thought of interest to club two different pharmacophores-oxadiazole and 8HQ for enhancement of biological activity. The present communication comprises the synthesis, characterization and antimicrobial study of a novel clubbed molecule 3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione(HAMMOT) and some transition metal complexes of it.


Methodology

Experimental

Melting points were determined by standard open capillary method and are uncorrected. Elemental analysis was performed with Perkins Elmer (USA) 2400-II CHN analyzer. The FT-IR spectra were recorded on Perkin Elmer Spectrum GX spectrophotometer using KBr pellets. The ¹H NMR spectra were recorded on Bruker 400 MHz instrument using DMSO-d₆ as solvent and TMS as internal reference standard. Magnetic moments were determined by the Gouy method using mercury tetrathiocyanatocobaltate(II) [HgCo(NCS)₄] as calibrant and the diamagnetic correction was made using Pascal's constant. The metal contents of the complexes were analyzed by EDTA titration after decomposing the organic matter with HClO₄, H₂SO₄ and HNO₃ (1:1.5:2.5) mixture⁵⁵.

Synthesis of novel clubbed molecule (HAMMOT)

First of all 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione was prepared as per reported procedures⁵⁶⁻⁵⁷. Then, novel clubbed molecule 3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione (HAMMOT) was synthesized through Mannich condensation reaction⁵⁸⁻⁵⁹ of 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione with formaldehyde and 5-amino-8-hydroxyquinoline hydrochloride (Scheme 1). A mixture of 5-amino-8-hydroxyquinoline hydrochloride (0.01 mol), 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione (0.01 mol), formaldehyde (0.03 mol) and few drops of concentrated hydrochloric acid in isopropanol (50 mL) was stirred and warmed on the steam bath for about ten hours. End of reaction was monitored by TLC. Then isopropanol was distilled out and water was added to extract product into aqueous layer. Methylene dichloride (50 mL) was charged to extract impurities and aqueous layer basified using 10% NaOH solution and extract product in methylene dichloride (2 X 50 mL). Finally organic layer dried over Na₂SO₄ and distilled out atmospherically and finally apply vacuum to get a product. The physicochemical parameters and characteristic FT-IR frequencies are presented in Tables 1 and 2 respectively.



3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione

Scheme 1

General procedure for the synthesis of metal complexes

Metal (II) complexes were synthesized using reported procedure⁶⁰. A hot solution of transition metal (II) salt (2.5 mmol) in 50% aqueous formic acid (2.5 mL) was added drop-wisely with continuous stirring to the hot 20% aqueous formic acid solution (20 mL) of HAMMOT (5 mmol). With the proper adjustment of the pH (~8.5) using 50% NH₄OH solution, the resultant mixture was further digested for 4 hours in the water bath (Scheme 2). The obtained solid product was filtered, washed with hot water, and subsequently with small quantity of ethanol, acetonitrile and dried in a vacuum desiccator. The physicochemical parameters and characteristic FT-IR frequencies of metal (II) complexes are summarized in Tables 1 and 2 respectively.

In vitro evaluation of antibacterial and antifungal activity

Novel clubbed molecule HAMMOT and its metal (II) complexes were screened for in vitro antimicrobial activity against the representative panel of two Gram-positive and two Gram-negative bacterial strains and two strains of fungi⁶¹ taking ciprofloxacin as a reference standard drug. To evaluate antimicrobial activities, agar cup plate method was used. Antibacterial activities were evaluated against Gram-positive bacterial strains: *Staphylococcus aureus*, *Bacillus subtilis* and Gram-negative bacterial strains: *Escherichia coli*, *Pseudomonas aeruginosa* at 50 µg/mL concentration. Zone of inhibition was recorded in mm. Antifungal activities were evaluated against fungal strains: *Aspergillus niger* and *Aspergillus flavus* at 1000 ppm concentration. Newly synthesized compounds exhibited moderate to good inhibitory action towards test organisms.

Results and Discussion

The synthesized 3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole-2(3H)-thione (HAMMOT) appears as colourless crystals. It is partially soluble in acetone, methanol, ethanol and acetonitrile, while it is soluble in polar organic solvents like dimethylformamide (DMF), dimethylsulphoxide (DMSO), organic acids and pyridine. Metal (II) complexes [M(II) (HAMMOT)₂(H₂O)₂] have characteristic colour, are stable in air, and are practically insoluble in water, ethanol, methanol, chloroform and hexane.

The FT-IR spectra of HAMMOT and its metal complexes demonstrating all the important stretching and bending vibrations in appropriate region are summarized in Table 2. In the spectrum of HAMMOT the

absorption band at 3299 cm^{-1} is due to O-H stretching vibration and the strong band at 1408 cm^{-1} to O-H bending vibration⁶². The CH₂ group shows C-H stretching vibration band at 2968 cm^{-1} . The bands at 1596 cm^{-1} for C=N, at 1500 cm^{-1} for C=C and at 1478 cm^{-1} for C-C bond, assigned to the aromatic skeletal stretching vibrations of parent heterocyclic ring⁶². The N-H stretching vibrations appeared near 3240 cm^{-1} , while N-H and C-N bending vibrations appeared at 1657 and 1263 cm^{-1} , respectively. However, a comparison of IR spectra of ligand and its metal (II) coordinated complexes exhibited some significant characteristic differences⁶³. One of the considerable differences to be expected was the presence of more broadened band in the region of $2700\text{-}3400\text{ cm}^{-1}$ for the chelates. As the oxygen atom of the OH group of the ligand forms a coordination bond with the metal ions, the broadening of this band may be attributed to the presence of coordinated water molecules⁶⁴. The band due to the C=N stretching vibration at around 1596 cm^{-1} was shifted to lower frequency, whereas, the band at 1408 cm^{-1} in the spectrum of HAMMOT assigned to in-plane OH deformation was shifted towards higher frequency in the spectra of the chelates due to the formation of M-O bond⁶⁵. This has been further confirmed by the presence of a weak band at 1095 cm^{-1} for C-O-M stretching mode, while bands around $\sim 770\text{ cm}^{-1}$ and $\sim 523\text{ cm}^{-1}$ correspond to the N→M vibration⁶⁶. All these characteristics features of the FT-IR studies unveil the formation of HAMMOT and metal (II) complexes. Structural analysis of the ligand was also carried out with the help of ¹H NMR using DMSO-d₆ at room temperature. In case of ¹H NMR spectrum of HAMMOT exhibited 3.82 (d, 2H, -CH₂-), 5.84 (t, 1H, NH), 6.74-7.92 (m, 8H, Ar-H), 9.00 (dd, 1H, H₂ of quinoline), 9.72 (bs, 1H, OH). ¹H-NMR spectrum of [Zn(HAMMOT)₂] exhibited 3.90 (d, 4H, -CH₂-), 5.82 (t, 2H, NH), 6.58-8.05 (m, 16H, Ar-H), 8.94 (dd, 2H, H₂ of quinoline). By comparing the ¹H-NMR data of the ligand and the metal complex of Zn(II), it was concluded that, a broad singlet at δ 9.72 ppm due to the OH proton⁶⁷ will disappear in the spectrum of Zn(II) complex suggested that this proton has been lost due to coordination of oxygen atom to the metal ion⁶⁸. The H₂ signal of the Zn(II) complex appeared at low magnetic field (δ 9.00) compared to that of ligand (δ 8.94), suggesting the involvement of N1 in the formation of complex. The absorptions of all quinoline protons are slightly downfield shifted; except H₇ which is upfield shifted⁶⁹ which further indicate the coordination of oxygen atom to metal ion. The results of the magnetic moment value (Table 1) were shown to have octahedral geometry for all the metal complexes. Table 1 Physicochemical parameters of ligand (HAMMOT) and its metal complexes

Empirical formula of ligand / metal complexes	Mole. Weight	% Yield	m.p. (°C)	Elemental Analysis				μ_{eff}	
				calc. % (found %)				B.M. metal (expected)	
				C	H	N	S		
HAMMOT	380	70	165	60.00	4.21	14.73	8.42	--	--
C ₁₉ H ₁₆ N ₄ O ₃ S				(60.0)	(4.2)	(14.7)	(8.4)		
[Mn(HAMMOT) ₂ (H ₂ O) ₂]				53.71	4.00	13.19	7.53	6.47	5.56
C ₃₈ H ₃₄ Mn ₂ N ₈ O ₈ S ₂	849	66	>300	(53.69)	(3.96)	(13.15)	(7.50)	(6.45)	(5.2-6.0)
[Co(HAMMOT) ₂ (H ₂ O) ₂]	853	65	>300	53.45	3.98	13.13	7.50	6.91	4.92
C ₃₈ H ₃₄ Co ₂ N ₈ O ₈ S ₂				(53.41)	(3.94)	(13.10)	(7.48)	(6.88)	(4.4-5.2)
[Ni(HAMMOT) ₂ (H ₂ O) ₂]	853	67	>300	53.45	3.98	13.13	7.50	6.91	3.24
C ₃₈ H ₃₄ Ni ₂ N ₈ O ₈ S ₂				(53.42)	(3.93)	(13.10)	(7.49)	(6.87)	(2.9-3.4)
[Cu(HAMMOT) ₂ (H ₂ O) ₂]	857.5	62	>300	53.17	3.96	13.06	7.46	7.40	1.80
C ₃₈ H ₃₄ Cu ₂ N ₈ O ₈ S ₂				(53.15)	(3.93)	(13.00)	(7.45)	(7.38)	(1.7-2.2)

[Zn(HAMMOT)2(H2O)2] 859 64 >300 53.08 3.95 13.03 7.45 7.56 diamagnetic
 C38H34ZnN8O8S2 (53.00) (3.94) (13.00)(7.43) (7.50)

Table 2 FT-IR spectral frequencies of ligand (HAMMOT) and its metal complexes (in cm⁻¹)

Compound	$\nu(\text{O-H})$	$\nu(\text{C=N})$	$\nu(\text{N-M})$	$\nu(\text{N-M})$	$\nu(\text{O-M})$	$\nu(\text{C-O-M})$
[Mn(HAMMOT)2(H2O)2]	3370(br)	1566	521	768	1423	1091
[Co(HAMMOT)2(H2O)2]	3376(br)	1573	522	763	1424	1092
[Ni(HAMMOT)2(H2O)2]	3373(br)	1569	518	772	1421	1097
[Cu(HAMMOT)2(H2O)2]	3375(br)	1578	524	770	1427	1089
[Zn(HAMMOT)2(H2O)2]	3372(br)	1571	521	764	1420	1093
HAMMOT	3299	1596	--	--	--	--

Table 3 Antimicrobial activities of ligand (HAMMOT) and its metal complexes

Compound	Zone of inhibition (mm) ^a					
	Antibacterial activity				Antifungal activity	
	S.aureus	B.subtillis	E.coli	P.aerugionsa	A.niger	A.flavus
5AHQ	24	22	26	22	21	19
HAMMOT	31	32.5	29	30	36	33
[Mn(HAMMOT)2(H2O)2]	15	13	13	14	12	11
[Co(HAMMOT)2(H2O)2]	17.6	15.5	16	16.5	13	17
[Ni(HAMMOT)2(H2O)2]	18.5	17	13	18	15	16
[Cu(HAMMOT)2(H2O)2]	22	23.5	22	20	21	20
[Zn(HAMMOT)2(H2O)2]	14.5	15	11	11.5	13	14
Ciprofloxacin	28	42	26	35	44	38

Results are taken in triplicate and average is shown.

CONCLUSION

The brand-new compound 3-(((8-hydroxyquinolin-5-yl)amino)methyl)-5-(4-methoxyphenyl) 1,3,4-oxadiazole-2(3H)-thione (HAMMOT) and its 1:1:2 metal to ligand ratio octahedral metal (II) complexes were created and described. Compared to 8-hydroxyquinoline, they had moderate to good antibacterial and antifungal properties. This might be because of the parent compounds' combined biological impact of lipophilicity or because of the metal chelating capabilities. Cu(II) complex was the most active of the complexes, with activity equivalent to that of ciprofloxacin but lower than that of HAMMOT.

References

1. Sun X-Y, Wu R, Wen X, Guo L, Zhou C-P, Li J, Quan Z-S & Bao J, *Eur J Med Chem*, 60, 2013, 451.
2. Li S, Wang Z, Wei Y, Wu C, Gao S, Jiang H, Zhao X, Yan H & Wang X, *Biomaterials*, 34, 2013, 902.
3. Muregi FW, Ishih A, *Drug Develop Res*, 71, 2010, 20.
4. Block JH, Wilson and Giswold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 11th Ed, Lippincott Williams and Wilkins, Philadelphia, 2005.
5. Short BR, Vargas MA, Thomas JC, O'Hanlon S, Enright MC, *J Antimicrob Chemother*, 57(1), 2006, 104–109.
6. Albrecht M, Fiege M, Osetska O, *Coord Chem Rev*, 252(8–9), 2008, 812–824.
7. Vanparia SF, Patel TS, Sojitra NA et al, *Acta Chim Slov*, 57(3), 2010, 600–667.
8. Pierre JL, Baret P, Serratrice G, *Curr Med Chem*, 10, 2003, 1077.
9. Singh S, Bharti N, Mohapatra PP, *Chem Rev*, 109, 2009, 1900.
10. Mekheimer R, Ahmed EK, Khattab AF, *Bull Chem Soc Japan*, 66, 1998, 2936.
11. Yamato M, Ando J, Sakaki K et al, *J Med Chem*, 35, 1992, 267.
12. Tōgu V, Palumaa P, *Coord Chem Rev*, 256(19–20), 2012, 2219–2224.
13. Zheng H, Gal S, Weiner LM et al, *J Neurochem*, 95(1), 2005, 68–78.
14. Ding WQ, Lind SE, *IUBMB Life*, 61(11), 2009, 1013–1018.
15. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP, *Breast Cancer Res*, 7(6), 2005, R897–R908.
16. Chen D, Cui QC, Yang H et al, *Cancer Res*, 67(4), 2007, 1636–1644.
17. Mao X, Li X, Sprangers R et al, *Leukemia*, 23(3), 2009, 585–590.
18. Pavlov A, Takuchev N, Georgieva N, *Biotechnol Biotechnol Equip*, 26(1), 2011, 164–169.
19. Jeon JH, Lee CH, Lee HS, *J Korean Soc Appl Biol Chem*, 52(2), 2009, 202–205.
20. Ahmed SM, Ismail DA, *J Surf Deter*, 11(3), 2008, 231–235.
21. Strobl JS, Seibert CW, Li Y et al, *J Parasitol*, 95(1), 2009, 215–223.
22. Scheibel LW, Adler A, *Mol Pharmacol*, 22(1), 1982, 140–144.
23. Madrid PB, Sherrill J, Liou AP, Weisman JL, Derisi JL, Guy RK, *Bioorg Med Chem Lett*, 15(4), 2005, 1015–1018.
24. Moret V, Dereudre-Bosquet N, Clayette P et al, *Bioorg Med Chem Lett*, 16(23), 2006, 5988–5992.
25. Darby CM, Nathan CF, *J Antimicrob Chemother*, 65(7), 2010, 1424–1427.
26. Warner VD, Musto JD, Sane JN, Kim KH, Grunewald GL, *J Med Chem*, 20(1), 1977, 92–96.
27. Tanzer JM, Slee AM, Kamay B, Scheer E, *Antimicrob Agents Chemother*, 13(6), 1978, 1044–1045.
28. Tennant RW, Margolin BH, Shelby MD et al, *Science*, 236, 1987, 933. 29 Fraser RSS, Creanor J, *Eur J Biochem*, 46, 1974, 67-73.
29. Leanderson P, Tagesson C, *Carcinogenesis*, 17, 1996, 545. 31 Hecht SM, *Fed Proc*, 45(12), 1986, 2784–2791
30. Anjaneyulu Y, Rao RP, Swamy RY, Eknath A, Rao KN, *Proc Ind Acad Sci (Chem Sci)*, 91(2), 1982, 157–163.

31. Paget SD, Foleno BD, Bogges CM, Goldschmidt RM, Hlasta DJ, Weidnerwells MA, Werblood HM, Wira E, Bush K, Macielag MJ, *Bioorg Med Chem Lett*, 13, 2003, 4173-4177.
- 32 Albert A, Gibson MI, Rubbo SD, *Br J Exp Pathol*, 34(2), 1953, 119–130.
- 33 Srisung S, Suksrichavalit T, Prachayasittikul S, Ruchirawat S, Prachayasittikul V, *Int J Pharmacol*, 9(2), 2013, 170–175.
- 34 Rohde W, Mikelens P, Jackson J, Blackman J, Whitcher J, Levinson W, *Antimicrob Agents Chemother*, 10(2), 1976, 234–240.
- 35 Moustafa AH, Saad HA, Shehab WS, El-Mobayed MM, *Phosphorus, Sulfur, Silicon & the Related Elements*, 183(1), 2008, 115-135.
- 36 Kadi AA, El-Brollosy NR, Al-Deeb OA, Habib EE, Ibrahim TM, El-Emam AA, *Eur J Med Chem*, 429(2), 2007, 235-242.
- 37 Küçükgülzel G, Kocatepe A, de Clercq E, Sahin F, Güllüce M, *Eur J Med Chem*, 41(3), 2006, 353-359.
- 38 Lohray BB, Lohray VB, Srivastava BK, Kapadnis PB, Pandya P, *Bioorg Med Chem*, 12, 2004, 4557-4564.
- 39 Lohray BB, Lohray VB, Srivastava BK, Gupta S, Solanki M, Kapadnis PB, Takale V, Pandya P, *Bioorg Med Chem Lett*, 14, 2004, 3139-3142.
- 40 Weidner-Wells M, Werblood HM, GoldschmidtR, Bush K, Foleno BD, Hilliard JJ, Melton J, Wira E, Macielag MJ, *Bioorg Med Chem Lett*, 14, 2004, 3060-3072.